Abstract
Summary
• The Asthma Impairment and Risk Questionnaire (AIRQ®) has been designed and tested to measure patients’ levels of asthma control in a healthcare setting.
• Unlike other available questionnaires that only assess asthma symptoms that can be bothersome or limit a person’s activities and quality of life (impairment-related symptoms), the AIRQ also includes questions related to risk of an asthma attack. This allows for a broader measurement of asthma control and a prediction of the chance of having future asthma attacks.
• AIRQ scores are linked to a patient’s own experience of their health and how it impacts their daily life (health-related quality of life).
• The AIRQ may make it easier for patients and healthcare professionals to have shared decision-making discussions that can lead to better asthma care and asthma outcomes.
• This document summarizes several published studies of the AIRQ in people with asthma.
Footnotes
Acknowledgements
The authors would like to thank the patients, investigators, and experts who participated in the development and validation of the AIRQ. Medical writing services were provided by Jacqueline Register, MS, and Karen Kurtyka, MPH, of Oxford PharmaGenesis (Newtown, PA, United States), which were in accordance with Good Publication Practice (GPP 2022) and funded by AstraZeneca (Wilmington, DE, United States).